CTOs on the Move

Hematology-Oncology Associates of Central New Yo

www.hoacny.com

 
Hematology-Oncology Associates of Central New York is a East Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.hoacny.com
  • 5008 Brittonfield Pkwy
    East Syracuse, NY USA 13057
  • Phone: 315.634.5056

Executives

Name Title Contact Details

Similar Companies

Sunquest Information Systems

Sunquest Information Systems, Inc. provides healthcare information systems to large and mid-sized hospitals, clinics and other facilities, including integrated delivery networks comprised of multi-entity, multi-site healthcare organizations.

Difference Card

The Difference Card helps organizations build the most cost effective health plan. Since 2001, The Difference Card has provided its clients with an average net savings of over 18%. The product utilizes proprietary medical reimbursement systems, risk transfer solutions and wellness strategies. In doing so, The Difference Card has delivered millions of dollars in savings to its clients while at the same time providing the highest level of employee benefits. With 13 offices across the United States, The Difference Card provides a national presence combined with local expertise and service. Through strategic broker partnerships, The Difference Card delivers custom plan design solutions that exceeds the needs of both employers and employees across the country.

BlueCross BlueShield of Louisiana

BlueCross BlueShield of Louisiana is a Baton Rouge, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brauer and Associates

Brauer and Associates is a Elmhurst, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.